ACOG, SMFM, and AAP Statement on Nirsevimab Shortage

• 2023

  Log in to bookmark this resource.

  Log in

---

Access Resources

• Job AidEN
• Ask aRCie About This Resource

About

This statement describes a shortage of nirsevimab and provides further recommendations. ACOG and SMFM recommend Pfizer’s RSVpreF vaccine for pregnant women as an alternative. Pediatricians should prioritize nirsevimab for high-risk infants according to CDC guidelines. ACOG and SMFM are addressing challenges in cost and access for maternal RSV vaccination, encouraging clinicians to stock and administer the vaccine. Clear documentation of vaccination is crucial, as infants protected by maternal vaccination may not need nirsevimab.

---

Tags

Focus Area: Infectious Disease

Audience: Physicians

Emergency Management Stage: Preparedness (Prevention / Protection)

Bundles: Nirsevimab Library

Keywords: Infant; Pregnant Women; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Antibodies, Monoclonal, Humanized; Health Equity

Institutions: American College of Obstetricians and Gynecologists

---

More like this

Boarding of Pediatric Patients in the Emergency Department 2024 · American College of Emergency Physicians California Hospital Association (CHA) COVID Tracking Tool 2021 · California Department of Public Health Pediatric Preparedness Resource Kit 2025 · American Academy of Pediatrics (AAP)

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---